In 2008, ACTIVE BIOTECH filed Oppositions against two JENOMIC patents with claims covering ACTIVE BIOTECH's key cancer drug ANYARA.  In hearings held at the Hague in 2008,  the Opposition Panel rejected ACTIVE BIOTECH's bid to revoke the patents.  The Board upheld JENOMIC's key  patent claims covering  ANYARA both struturally and functionally. Dissatisfied with the verdict  ACTIVE BIOTECH  appealed but withdrew its appeal voluntarily in 2012.  Both JENOMIC patents were issued in the EPO with claims covering ANYARA. The minutes and verdict of the Opposition proceedings are provided below.

ACTIVE BIOTECH 1st OPPOSITION REBUFFED BY EPO & APPEAL WITHDRAWN (2010)
Active Defeated in Two 2008 European Opp[...]
Adobe Acrobat document [867.5 KB]
ACTIVE BIOTECH 2nd OPPOSITION REJECTED BY EPO
wild type superantigen final verdict wit[...]
Adobe Acrobat document [306.2 KB]

About Jenomic Research Institute

 

Jenomic is a biotech company devoted to developing novel drugs and drug vehicles for treatment of cancer. These efforts are supported by a raft of peer- reviewed publications and worldwide patents/patent applications.

 

The research team is led by David S. Terman, MD, an emeritus member of the American Society of Clinical Investigation (academia's physician-scientist honor society), former Professor  of Medicine, Microbiology and Immunology and Founding Director of Cancer Biology Program at Baylor College of Medicine. He is currently Adjunct Professor of Biochemistry and Molecular Biology at UAB in Birmingham. Dr. Terman is cited in Who's Who in America 2008-2013

As seen in the Monterey Herald

Cancer researcher David S. Terman stands among piles of research and patent paperwork in his home office in Pebble Beach on Friday. Terman runs the Jenomic Research Institute in Carmel. (DAVID ROYAL/The Herald)